We propose to create the North American AIDS Cohort Collaboration on Research and Design (NAACCORD) in response to the International Databases to Evaluate AIDS RFA. The NA-ACCORD is designed to be widely representative of HIV care in the United States and Canada, and is comprised of both academic medical centers and community-based facilities that deliver HIV primary and specialty care. Further, it combines classical epidemiologic and clinical HIV cohorts in a unique and robust collaboration that includes both HIV-seropositive and seronegative persons. The NA-ACCORD consists of three major Cores - Administrative, Data Management, and Epidemiology/Biostatistics - that provide an infrastructure for efficient regional data collection and management, and the conduct of analyses to answer scientific questions of importance. Critical to our structure is the collaboration of investigators with a high level of scientific and methodologic expertise and HIV clinical experience to both identify questions of intraregional and interregional importance, and design and implement the analyses necessary to answer these questions. Our Core Aims are designed to answer questions that we have identified as most critical to the contemporary treatment of HIV-infection in North America. A large and growing number of HIV-infected persons in North America have received multiple antiretroviral (ARV) regimens with few apparent options for continuing treatment because of HIV resistance. The optimal management of these patients is unclear, and there are substantial methodologic challenges in addressing this issue. The rapid expansion of ARV options, with changes in tolerability, toxicity and dosing, make questions about when to begin ARVs and optimal sequencing of ARV therapy important to now address. Additional aims will leverage our combined large sample size and duration of follow-up to focus on identifying uncommon adverse events from new HIV therapies, long-term issues such as development of malignancy and effects of aging on HIV therapeutic response, developing new methods for observational HIV research and using our combined specimen repositories for pharmacogenetic and other transitional research. Appropriately, our Aims are most relevant to North America;however, they will also be generalizable to other regions where HAART is available (i.e., Western Europe), and will inform future HIV practice as it evolves in transitional and developing regions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI069918-05
Application #
7923864
Study Section
Special Emphasis Panel (ZAI1-JB-A (J3))
Program Officer
Zimand, Lori B
Project Start
2006-07-01
Project End
2011-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
5
Fiscal Year
2010
Total Cost
$1,710,138
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Buchanan, Ashley L; Hudgens, Michael G; Cole, Stephen R et al. (2018) Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights. J R Stat Soc Ser A Stat Soc 181:1193-1209
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
IeDEA and COHERE Cohort Collaborations (2018) Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clin Infect Dis 66:893-903
Eyawo, Oghenowede; McGinnis, Kathleen A; Justice, Amy C et al. (2018) Alcohol and Mortality: Combining Self-Reported (AUDIT-C) and Biomarker Detected (PEth) Alcohol Measures Among HIV Infected and Uninfected. J Acquir Immune Defic Syndr 77:135-143
Oh, Eric J; Shepherd, Bryan E; Lumley, Thomas et al. (2018) Considerations for analysis of time-to-event outcomes measured with error: Bias and correction with SIMEX. Stat Med 37:1276-1289
Lesko, Catherine R; Jacobson, Lisa P; Althoff, Keri N et al. (2018) Collaborative, pooled and harmonized study designs for epidemiologic research: challenges and opportunities. Int J Epidemiol 47:654-668
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Lee, Jennifer S; Cole, Stephen R; Achenbach, Chad J et al. (2018) Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy. PLoS One 13:e0197665

Showing the most recent 10 out of 160 publications